sulfadiazine has been researched along with Disease Models, Animal in 39 studies
Sulfadiazine: One of the short-acting SULFONAMIDES used in combination with PYRIMETHAMINE to treat toxoplasmosis in patients with acquired immunodeficiency syndrome and in newborns with congenital infections.
sulfadiazine : A sulfonamide consisting of pyrimidine with a 4-aminobenzenesulfonamido group at the 2-position.
diazine : The parent structure of the diazines.
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The effectiveness of combinations of rifabutin with atovaquone, clindamycin, pyrimethamine, or sulfadiazine in the treatment of toxoplasmic encephalitis in a murine model was investigated." | 7.69 | Use of rifabutin in combination with atovaquone, clindamycin, pyrimethamine, or sulfadiazine for treatment of toxoplasmic encephalitis in mice. ( Araujo, FG; Remington, JS; Suzuki, Y, 1996) |
| "Trimethoprim-sulfadiazine and gentamicin sulfate decreased early mortality in an established model of fibrinous peritonitis in the rat." | 7.67 | Efficacies of trimethoprim-sulfadiazine and gentamicin sulfate in the treatment of fibrinous peritonitis in rats. ( Benson, CE; Emms, SG, 1987) |
| "Co-trimazine, a new combination of trimethoprim and sulphadiazine intended for treatment of urinary tract infections, was tested and compared to co-trimoxazole in an experimental model of acute, obstructive pyelonephritis in the rat." | 7.66 | Efficacy of two trimethoprim-sulphonamide combinations in experimental pyelonephritis in the rat. ( Ritzerfeld, W, 1979) |
| "Hydrogen-rich water has a significant protective effect on OGD/R-causing HT22 cell injury, and the mechanism may be related to the inhibition of autophagy." | 4.40 | Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19. ( , 2023) |
| " Notably, the anti-parasitic drugs pyrimethamine and sulfadiazine, a standard treatment of toxoplasmosis, significantly reduced 3-HK and KYNA levels in the brain of infected mice when applied between 28 and 56 days post-infection." | 3.80 | Evaluation of kynurenine pathway metabolism in Toxoplasma gondii-infected mice: implications for schizophrenia. ( Fang, Q; Harris, TH; Horning, KJ; Hunter, CA; Notarangelo, FM; Schwarcz, R; Thomas, MA; Wilson, EH, 2014) |
| "The effectiveness of combinations of rifabutin with atovaquone, clindamycin, pyrimethamine, or sulfadiazine in the treatment of toxoplasmic encephalitis in a murine model was investigated." | 3.69 | Use of rifabutin in combination with atovaquone, clindamycin, pyrimethamine, or sulfadiazine for treatment of toxoplasmic encephalitis in mice. ( Araujo, FG; Remington, JS; Suzuki, Y, 1996) |
| "Trimethoprim-sulfadiazine and gentamicin sulfate decreased early mortality in an established model of fibrinous peritonitis in the rat." | 3.67 | Efficacies of trimethoprim-sulfadiazine and gentamicin sulfate in the treatment of fibrinous peritonitis in rats. ( Benson, CE; Emms, SG, 1987) |
| "Co-trimazine, a new combination of trimethoprim and sulphadiazine intended for treatment of urinary tract infections, was tested and compared to co-trimoxazole in an experimental model of acute, obstructive pyelonephritis in the rat." | 3.66 | Efficacy of two trimethoprim-sulphonamide combinations in experimental pyelonephritis in the rat. ( Ritzerfeld, W, 1979) |
| " While not preventing this destruction of heat-injured epithelium by Travase, simultaneous use of topical silver sulfadiazine cream did reduce the weight loss and purulence associated with Travase therapy of burns." | 3.65 | The effect of Travase on heat-injured skin. ( Zawacki, BE, 1975) |
| "In this study, the effects of the treatment with different doses of fluconazole (FLZ) in combination with the current treatment of acute toxoplasmosis on reducing the mortality rate and the parasitic load in the murine model in vivo were studied." | 1.62 | Determination of parasitic burden in the brain tissue of infected mice in acute toxoplasmosis after treatment by fluconazole combined with sulfadiazine and pyrimethamine. ( Anita, M; Hadi, M; Mohammad, JM; Reza, S; Sina, S; Soudabeh, E, 2021) |
| "The aim of this study is to evaluate the effects of pyrimethamine (PYR) and sulfadiazine (SDZ) combined with levamisole and echinacea on the survival of mice infected with Toxoplasma gondii." | 1.43 | In Vivo Efficacy of Drugs against Toxoplasma gondii Combined with Immunomodulators. ( Bilgin, K; Hokelek, M; Köksal, ZŞ; Yanik, K; Yılmaz, EM, 2016) |
| "Fluconazole is an important antifungal triazole used against others CNS related opportunistic pathogens such as Cryptococcus neoformans and Candida spp." | 1.39 | Toxoplasma gondii: the effect of fluconazole combined with sulfadiazine and pyrimethamine against acute toxoplasmosis in murine model. ( de Souza, W; Martins-Duarte, ÉS; Vommaro, RC, 2013) |
| "Sulfadiazine was withdrawn after 14-21 days to allow reactivation." | 1.34 | The timing of sulfadiazine therapy impacts the reactivation of latent Toxoplasma infection in IRF-8-/- mice. ( Jost, C; Liesenfeld, O; Reiter-Owona, I, 2007) |
| "Trimethoprim/sulfadiazine treatment resulted in a marked reduction of viable bacteria in the tissue chamber but did not eliminate the infection, resulting in abscessation from day 19 onwards in all six ponies." | 1.33 | Clinical efficacy of prophylactic administration of trimethoprim/sulfadiazine in a Streptococcus equi subsp. zooepidemicus infection model in ponies. ( Bosch, G; Ensink, JM; van Duijkeren, E, 2005) |
| "Mice treated with buprenorphine and not infected with T." | 1.33 | Buprenorphine does not affect acute murine toxoplasmosis and is recommended as an analgesic in Toxoplasma gondii studies in mice. ( Dubey, JP; Goodwin, DG; Kaur, T; Lindsay, DS; Mitchell, SM; Strobl, J, 2005) |
| "The activity of recombinant bactericidal/permeability-increasing protein (rBPI21), alone or in combination with sulfadiazine, on the intracellular replication of Toxoplasma gondii was assessed in vitro and in mice with acute toxoplasmosis." | 1.30 | Recombinant bactericidal/permeability-increasing protein (rBPI21) in combination with sulfadiazine is active against Toxoplasma gondii. ( Araujo, FG; Khan, AA; Lambert, LH; Remington, JS, 1999) |
| "A rabbit serosal scarification model was utilized to compare the ability of four drugs, previously administered peri-operatively to horses undergoing exploratory celiotomy, to prevent the development of postoperative intestinal adhesions." | 1.29 | Utilization of the serosal scarification model of postoperative intestinal adhesion formation to investigate potential adhesion-preventing substances in the rabbit. ( Barker, IK; Conlon, PD; Hurtig, MB; Livesey, MA; Singer, ER, 1996) |
| " Administration of the TMP-SDZ combination at a dosage of 30 mg/kg once daily was not effective in maintaining TMP or SDZ concentrations above the MIC of TMP-SDZ for the S aureus (0." | 1.27 | Serum and synovial fluid steady-state concentrations of trimethoprim and sulfadiazine in horses with experimentally induced infectious arthritis. ( Bertone, AL; Jones, RL; McIlwraith, CW, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 14 (35.90) | 18.7374 |
| 1990's | 8 (20.51) | 18.2507 |
| 2000's | 5 (12.82) | 29.6817 |
| 2010's | 8 (20.51) | 24.3611 |
| 2020's | 4 (10.26) | 2.80 |
| Authors | Studies |
|---|---|
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 1 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Minuzzi, CE | 1 |
| Portella, LP | 1 |
| Bräunig, P | 1 |
| Sangioni, LA | 1 |
| Ludwig, A | 1 |
| Ramos, LS | 1 |
| Pacheco, L | 1 |
| Silva, CR | 1 |
| Pacheco, FC | 1 |
| Menegolla, IA | 1 |
| Farinha, LB | 1 |
| Kist, PP | 1 |
| Breganó, RM | 1 |
| Nino, BSL | 1 |
| Cardoso Martins, FD | 1 |
| Monica, TC | 1 |
| Ferreira, FP | 1 |
| Britto, I | 1 |
| Signori, A | 1 |
| Medici, KC | 1 |
| Freire, RL | 1 |
| Garcia, JL | 1 |
| Navarro, IT | 1 |
| Difante, CM | 1 |
| Flores Vogel, FS | 1 |
| Sina, S | 1 |
| Mohammad, JM | 1 |
| Reza, S | 1 |
| Anita, M | 1 |
| Soudabeh, E | 1 |
| Hadi, M | 1 |
| Slingerland, BCGC | 1 |
| Keehnen, M | 1 |
| Ouwerling, B | 1 |
| Tavakol, M | 1 |
| Snijders, SV | 1 |
| Verbrugh, HA | 1 |
| Vos, MC | 1 |
| Remarque, EJ | 1 |
| Langermans, JAM | 1 |
| van Wamel, WJB | 1 |
| Lang, D | 1 |
| Schott, BH | 1 |
| van Ham, M | 1 |
| Morton, L | 1 |
| Kulikovskaja, L | 1 |
| Herrera-Molina, R | 1 |
| Pielot, R | 1 |
| Klawonn, F | 1 |
| Montag, D | 1 |
| Jänsch, L | 1 |
| Gundelfinger, ED | 1 |
| Smalla, KH | 1 |
| Dunay, IR | 1 |
| Tyebji, S | 1 |
| Seizova, S | 1 |
| Garnham, AL | 1 |
| Hannan, AJ | 1 |
| Tonkin, CJ | 1 |
| Notarangelo, FM | 1 |
| Wilson, EH | 1 |
| Horning, KJ | 1 |
| Thomas, MA | 1 |
| Harris, TH | 1 |
| Fang, Q | 1 |
| Hunter, CA | 1 |
| Schwarcz, R | 1 |
| Köksal, ZŞ | 1 |
| Yanik, K | 1 |
| Bilgin, K | 1 |
| Yılmaz, EM | 1 |
| Hokelek, M | 1 |
| Eraky, MA | 1 |
| El-Fakahany, AF | 1 |
| El-Sayed, NM | 1 |
| Abou-Ouf, EA | 1 |
| Yaseen, DI | 1 |
| Lopes, CD | 1 |
| Silva, NM | 1 |
| Ferro, EA | 1 |
| Sousa, RA | 1 |
| Firminot, ML | 1 |
| Bernardes, ES | 1 |
| Roque-Barreira, MC | 1 |
| Pena, JD | 1 |
| Martins-Duarte, ÉS | 1 |
| de Souza, W | 1 |
| Vommaro, RC | 1 |
| Wang, ZL | 1 |
| Sun, PP | 1 |
| Li, TX | 1 |
| Li, SX | 1 |
| Ensink, JM | 1 |
| Bosch, G | 1 |
| van Duijkeren, E | 1 |
| Lindsay, DS | 2 |
| Kaur, T | 1 |
| Mitchell, SM | 1 |
| Goodwin, DG | 1 |
| Strobl, J | 1 |
| Dubey, JP | 2 |
| Jost, C | 1 |
| Reiter-Owona, I | 1 |
| Liesenfeld, O | 1 |
| Rode, H | 1 |
| de Wet, PM | 1 |
| Davies, MR | 1 |
| Cywes, S | 1 |
| Salisbury, RE | 1 |
| Bevin, AG | 1 |
| Steinkraus, GE | 1 |
| Enterline, DS | 1 |
| Araujo, FG | 3 |
| Suzuki, Y | 2 |
| Remington, JS | 3 |
| Singer, ER | 1 |
| Livesey, MA | 1 |
| Barker, IK | 1 |
| Hurtig, MB | 1 |
| Conlon, PD | 1 |
| Schoondermark-van de Ven, EM | 1 |
| Melchers, WJ | 1 |
| Galama, JM | 1 |
| Meuwissen, JH | 1 |
| Eskes, TK | 1 |
| Khan, AA | 1 |
| Lambert, LH | 1 |
| Kang, H | 1 |
| Parmley, S | 1 |
| Lim, S | 1 |
| Park, D | 1 |
| Ritzerfeld, W | 3 |
| Davidson, DE | 1 |
| Johnsen, DO | 1 |
| Tanticharoenyos, P | 1 |
| Hickman, RL | 1 |
| Kinnamon, KE | 1 |
| Zawacki, BE | 1 |
| Lin, T | 1 |
| Johnson, LL | 1 |
| Escajadillo, A | 1 |
| Frenkel, JK | 1 |
| Bertone, AL | 1 |
| Jones, RL | 1 |
| McIlwraith, CW | 1 |
| Malla, N | 1 |
| Goyal, M | 1 |
| Pillai, P | 1 |
| Ganguly, NK | 1 |
| Mahajan, RC | 1 |
| Emms, SG | 1 |
| Benson, CE | 1 |
| Prát, V | 5 |
| Hatala, M | 3 |
| Konícková, L | 5 |
| Loew, H | 1 |
| Dressler, DP | 1 |
| Skornik, WA | 1 |
1 review available for sulfadiazine and Disease Models, Animal
1 trial available for sulfadiazine and Disease Models, Animal
38 other studies available for sulfadiazine and Disease Models, Animal
| Article | Year |
|---|---|
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
Isolation and molecular characterization of Toxoplasma gondii from placental tissues of pregnant women who received toxoplasmosis treatment during an outbreak in southern Brazil.
Topics: Animals; Brazil; Coccidiostats; Disease Models, Animal; Disease Outbreaks; Female; Genotype; Humans; | 2020 |
Determination of parasitic burden in the brain tissue of infected mice in acute toxoplasmosis after treatment by fluconazole combined with sulfadiazine and pyrimethamine.
Topics: 14-alpha Demethylase Inhibitors; Acute Disease; Animals; Antiprotozoal Agents; Brain; Disease Models | 2021 |
An experimental Staphylococcus aureus carriage and decolonization model in rhesus macaques (Macaca mulatta).
Topics: Administration, Intranasal; Animals; Anti-Bacterial Agents; Carrier State; Disease Models, Animal; D | 2018 |
Chronic Toxoplasma infection is associated with distinct alterations in the synaptic protein composition.
Topics: Animals; Antiprotozoal Agents; Brain; Chronic Disease; Cytokines; Disease Models, Animal; Gene Expre | 2018 |
Impaired social behaviour and molecular mediators of associated neural circuits during chronic Toxoplasma gondii infection in female mice.
Topics: Amygdala; Animals; Behavior, Animal; Brain; Cognition; Disease Models, Animal; Female; Hippocampus; | 2019 |
Evaluation of kynurenine pathway metabolism in Toxoplasma gondii-infected mice: implications for schizophrenia.
Topics: Animals; Anti-Infective Agents; Brain; Disease Models, Animal; Drug Combinations; Female; Kynurenic | 2014 |
In Vivo Efficacy of Drugs against Toxoplasma gondii Combined with Immunomodulators.
Topics: Administration, Oral; Animals; Antiprotozoal Agents; Disease Models, Animal; Drug Therapy, Combinati | 2016 |
Effects of Thymus vulgaris ethanolic extract on chronic toxoplasmosis in a mouse model.
Topics: Animals; Brain; Chronic Disease; Disease Models, Animal; Ethanol; Humans; Male; Mice; Plant Extracts | 2016 |
Azithromycin reduces ocular infection during congenital transmission of toxoplasmosis in the Calomys callosus model.
Topics: Animals; Anti-Infective Agents; Antiprotozoal Agents; Azithromycin; Brain; Disease Models, Animal; D | 2009 |
Toxoplasma gondii: the effect of fluconazole combined with sulfadiazine and pyrimethamine against acute toxoplasmosis in murine model.
Topics: Acute Disease; Animals; Antifungal Agents; Antiprotozoal Agents; Cell Line; Cell Survival; Disease M | 2013 |
[Pulsatilla decoction treat inflammatory bowel disease by activating NLRP3].
Topics: Animals; Carrier Proteins; Caspase 1; Cytokines; Disease Models, Animal; Drugs, Chinese Herbal; Infl | 2012 |
Clinical efficacy of prophylactic administration of trimethoprim/sulfadiazine in a Streptococcus equi subsp. zooepidemicus infection model in ponies.
Topics: Administration, Oral; Animals; Anti-Bacterial Agents; Antibiotic Prophylaxis; Disease Models, Animal | 2005 |
Buprenorphine does not affect acute murine toxoplasmosis and is recommended as an analgesic in Toxoplasma gondii studies in mice.
Topics: Acute Disease; Analgesics, Opioid; Animals; Buprenorphine; Cell Line; Chlorocebus aethiops; Coccidio | 2005 |
The timing of sulfadiazine therapy impacts the reactivation of latent Toxoplasma infection in IRF-8-/- mice.
Topics: Animals; Antiprotozoal Agents; Brain; Disease Models, Animal; Drug Administration Schedule; Humans; | 2007 |
An experimental evaluation of the germicidal efficacy of three topical antimicrobial agents in burns.
Topics: Administration, Topical; Animals; Burns; Disease Models, Animal; Mafenide; Male; Povidone; Povidone- | 1981 |
Burn wound sepsis: effect of delayed treatment with topical chemotherapy on survival.
Topics: Administration, Topical; Animals; Burns; Cerium; Disease Models, Animal; Mafenide; Pseudomonas Infec | 1980 |
Use of rifabutin in combination with atovaquone, clindamycin, pyrimethamine, or sulfadiazine for treatment of toxoplasmic encephalitis in mice.
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Antiprotozoal Agents; Atovaquone; Brain; Clin | 1996 |
Utilization of the serosal scarification model of postoperative intestinal adhesion formation to investigate potential adhesion-preventing substances in the rabbit.
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Carboxymeth | 1996 |
Prenatal diagnosis and treatment of congenital Toxoplasma gondii infections: an experimental study in rhesus monkeys.
Topics: Amniotic Fluid; Animals; Anti-Infective Agents; Disease Models, Animal; DNA, Protozoan; DNA, Ribosom | 1997 |
Recombinant bactericidal/permeability-increasing protein (rBPI21) in combination with sulfadiazine is active against Toxoplasma gondii.
Topics: Animals; Antimicrobial Cationic Peptides; Antiprotozoal Agents; Blood Proteins; Cells, Cultured; Dis | 1999 |
Induction of tumor necrosis factor-alpha and inducible nitric oxide synthase fails to prevent toxoplasmic encephalitis in the absence of interferon-gamma in genetically resistant BALB/c mice.
Topics: Animals; Antigens, Protozoan; Antiprotozoal Agents; Brain; Disease Models, Animal; Encephalitis; Fem | 2000 |
Efficacy of two trimethoprim-sulphonamide combinations in experimental pyelonephritis in the rat.
Topics: Animals; Disease Models, Animal; Drug Administration Schedule; Drug Combinations; Escherichia coli I | 1979 |
Evaluating new antimalarial drugs against trophozoite induced Plasmodium cynomolgi malaria in rhesus monkeys.
Topics: Amodiaquine; Animals; Antimalarials; Dapsone; Disease Models, Animal; Dose-Response Relationship, Dr | 1976 |
The effect of Travase on heat-injured skin.
Topics: Administration, Topical; Animals; Body Weight; Burns; Debridement; Disease Models, Animal; Drug Eval | 1975 |
Synergistic combination of azithromycin and sulfadiazine for treatment of toxoplasmosis in mice.
Topics: Animals; Azithromycin; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Erythromyc | 1992 |
SCID mouse models of acute and relapsing chronic Toxoplasma gondii infections.
Topics: Acute Disease; Animals; Brain Diseases; Chronic Disease; Cysts; Disease Models, Animal; Lymphocytes; | 1992 |
Experimental toxoplasmosis and vaccine tests in Aotus monkeys.
Topics: Animals; Antibodies, Protozoan; Aotus trivirgatus; Disease Models, Animal; Female; Hypersensitivity, | 1991 |
Effects of sulfadiazine and amprolium on Neospora caninum (Protozoa: Apicomplexa) infections in mice.
Topics: Acute Disease; Amprolium; Animals; Disease Models, Animal; Encephalitis; Female; Mice; Picolines; Pn | 1990 |
Serum and synovial fluid steady-state concentrations of trimethoprim and sulfadiazine in horses with experimentally induced infectious arthritis.
Topics: Administration, Oral; Animals; Anti-Bacterial Agents; Arthritis, Infectious; Disease Models, Animal; | 1988 |
Experimental ocular toxoplasmosis with RH strain of Toxoplasma gondii.
Topics: Animals; Disease Models, Animal; Rabbits; Sulfadiazine; Toxoplasmosis, Ocular | 1988 |
Efficacies of trimethoprim-sulfadiazine and gentamicin sulfate in the treatment of fibrinous peritonitis in rats.
Topics: Animals; Disease Models, Animal; Drug Combinations; Gentamicins; Male; Peritonitis; Rats; Rats, Inbr | 1987 |
[Models of urinary infection].
Topics: Animals; Bacterial Infections; Bacteriuria; Carbenicillin; Disease Models, Animal; Drug Therapy, Com | 1974 |
[Effect of the combination of nitrofurantoin and sulfadiazine in experimental E. coli cystitis].
Topics: Animals; Bacteriuria; Cystitis; Disease Models, Animal; Escherichia coli Infections; Female; Nitrofu | 1972 |
[Experimental cystitis in rats and its chemotherapy].
Topics: Animals; Bacteriuria; Cystitis; Disease Models, Animal; Escherichia coli; Escherichia coli Infection | 1970 |
[Long-term therapy of experimental E. coli cystitis with combination of sulfadiazine and nitrofurantoin].
Topics: Animals; Cystitis; Disease Models, Animal; Drug Synergism; Escherichia coli Infections; Female; Nitr | 1971 |
Silver sulfadiazine and Sulfamylon cream in the burned rat model: a comparative evaluation.
Topics: Animals; Burns; Disease Models, Animal; Hydrogen-Ion Concentration; Liver; Lung; Ointments; Pharmace | 1970 |
[Comparison of the effects of gentamicin and other chemotherapeutic agents in experimental urinary tract infections].
Topics: Animals; Anti-Infective Agents; Cephalosporins; Colistin; Cystitis; Disease Models, Animal; Gentamic | 1970 |